Curium

Clinical Trial · NCT062356099

Phase 3 Trial of Copper Cu 64 PSMA I&T PET/CT Imaging in Men with Suspected Biochemical Recurrence of Prostate Cancer (Solar-Recur)

Overview

Solar-Recur is a single-arm prospective study. Local read of the copper Cu 64 PSMA I&T PET/CT can be used to inform patient management. For the primary endpoints, PET/CT scans will be read by blinded independent reviewers.

Sponsor

Curium

Contacts

Darcy Denner, Ph.D. (Clinical Trial Director)

darcy.denner@curiumpharma.com

ClinicalTrials.gov

NCT062356099

Drug / Compound

Isotope(s):
Target(s):

Educational Video

Eligibility

Inclusion

  • BCR of PC: Patients w/prior RP: PSA >.2 ng/mL w/confirm PSA value >.2, or w/prior radiation: 2ng/mL PSA rise over nadir
  • Male aged ≥18 years
  • Prior RP (>6 weeks prior to screening) or radiation therapy (>1 year prior to screening) with curative intent
  • Histologically proven prostate adenocarcinoma

Exclusion

  • ADT or other therapies targeting the Androgen pathway within 3 months. Pts w/rise in PSA while on ADT for >6 months
  • PSMA PET within 90 days prior to enrollment

Patient Education

Publications

Publications not yet provided.

Locations

Loading…